JP2016520573A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520573A5
JP2016520573A5 JP2016510807A JP2016510807A JP2016520573A5 JP 2016520573 A5 JP2016520573 A5 JP 2016520573A5 JP 2016510807 A JP2016510807 A JP 2016510807A JP 2016510807 A JP2016510807 A JP 2016510807A JP 2016520573 A5 JP2016520573 A5 JP 2016520573A5
Authority
JP
Japan
Prior art keywords
composition
angiotensin
patient
composition according
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016510807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520573A (ja
JP6522584B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/035511 external-priority patent/WO2014176534A1/en
Publication of JP2016520573A publication Critical patent/JP2016520573A/ja
Publication of JP2016520573A5 publication Critical patent/JP2016520573A5/ja
Priority to JP2019000124A priority Critical patent/JP6962943B2/ja
Application granted granted Critical
Publication of JP6522584B2 publication Critical patent/JP6522584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016510807A 2013-04-26 2014-04-25 腎不全を処置するための組成物及び方法 Active JP6522584B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019000124A JP6962943B2 (ja) 2013-04-26 2019-01-04 腎不全を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361816578P 2013-04-26 2013-04-26
US61/816,578 2013-04-26
PCT/US2014/035511 WO2014176534A1 (en) 2013-04-26 2014-04-25 Compositions and methods for treating renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000124A Division JP6962943B2 (ja) 2013-04-26 2019-01-04 腎不全を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016520573A JP2016520573A (ja) 2016-07-14
JP2016520573A5 true JP2016520573A5 (enExample) 2017-06-08
JP6522584B2 JP6522584B2 (ja) 2019-05-29

Family

ID=51792411

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016510807A Active JP6522584B2 (ja) 2013-04-26 2014-04-25 腎不全を処置するための組成物及び方法
JP2019000124A Active JP6962943B2 (ja) 2013-04-26 2019-01-04 腎不全を処置するための組成物及び方法
JP2021168488A Pending JP2022009125A (ja) 2013-04-26 2021-10-14 腎不全を処置するための組成物及び方法
JP2023177200A Pending JP2024009958A (ja) 2013-04-26 2023-10-13 腎不全を処置するための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019000124A Active JP6962943B2 (ja) 2013-04-26 2019-01-04 腎不全を処置するための組成物及び方法
JP2021168488A Pending JP2022009125A (ja) 2013-04-26 2021-10-14 腎不全を処置するための組成物及び方法
JP2023177200A Pending JP2024009958A (ja) 2013-04-26 2023-10-13 腎不全を処置するための組成物及び方法

Country Status (6)

Country Link
US (3) US9457059B2 (enExample)
EP (2) EP3858437A1 (enExample)
JP (4) JP6522584B2 (enExample)
CN (1) CN105592855A (enExample)
AU (4) AU2014256944B2 (enExample)
WO (1) WO2014176534A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
AU2014256944B2 (en) * 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
LT3607962T (lt) 2013-12-18 2026-01-12 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) * 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス,インコーポレイテッド 腹水の治療
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
EP3518910A4 (en) 2016-09-30 2020-11-04 Xenamed Corporation COMPOSITIONS OF MIDODRINE AND THEIR METHODS OF USE
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
JP7364568B2 (ja) 2017-12-22 2023-10-18 ゼナメッド コーポレーション 持続放出ミドドリン塩酸塩組成物及び使用方法
MX2020013389A (es) * 2018-06-15 2021-03-31 Ferring Bv Composiciones de terlipresina y usos de las mismas.
WO2020061416A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
JP7694400B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694401B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694406B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694404B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694403B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694405B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694407B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO2002098906A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) * 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
AU2014256944B2 (en) * 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure

Similar Documents

Publication Publication Date Title
Amao et al. Use of sugammadex in patients with a history of pulmonary disease
JP2022009125A5 (enExample)
Ochala et al. Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: underlying mechanisms
JP2020073529A5 (enExample)
JP2021167314A (ja) Gip/glp1アゴニスト組成物
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
Wang et al. Changes of learning and memory in aged rats after isoflurane inhalational anaesthesia correlated with hippocampal acetylcholine level
JP2016539921A5 (enExample)
MX2012012051A (es) Compuesto organico para usarse en el tratamiento de cancer de higado.
JP2014528901A5 (enExample)
JP7594045B2 (ja) 薬学的組成物
NZ598534A (en) Dosage regimen of an s1p receptor modulator
JP2016516074A5 (enExample)
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP2017519799A5 (enExample)
JP2012502103A5 (enExample)
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
JP2012525391A5 (enExample)
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
RU2014126070A (ru) Способы лечения и предотвращения глазных заболеваний
JP2019535830A5 (enExample)
KR20210126515A (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물